 Home > Active Ingredient News > Immunology News > BJD: Efficacy and safety of risacizumab vs. scocilizumab in patients with moderate to severe plaque psoriasis

BJD: Efficacy and safety of risacizumab vs. scocilizumab in patients with moderate to severe plaque psoriasis

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

repaglinide 2 mg

risperdal 2 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Patients with plaque psoriasis need more effective, safer, and more convenient biological treatments to improve their quality of life
.

Risankizumab and Suckinumab inhibit interleukin (IL)-23 and IL-17A, respectively, and are effective for adult patients with moderate to severe plaque psoriasis, but the dosage regimen is different

The study aims to directly compare the efficacy and safety of risankizumab and seckinumab within 52 weeks
.

Adult patients with chronic, moderate, and severe plaque psoriasis were randomly divided into Risankizumab 150 mg or Suckinumab 300 mg treatment groups at a ratio of 1:1, 30 cases in each group, and randomly divided into two groups, 30 cases in each group, respectively.

The main observation index is the proportion of patients whose psoriasis area severity index (≥90) was improved by 90% at the 16th week (non-inferiority comparison, 12% difference) and 52 weeks (advantage comparison)
.

Results 327 patients from 9 countries received risankizumab (n=164) or seckinumab (n=163) treatment
.

The proportion of patients with risankizumab reaching PASI90 at week 16 [73.

Conclusion: At 52 weeks of treatment, risankizumab showed superior efficacy and similar safety to seckinumab, but the frequency of medication was lower than that of seckinumab
.

Literature source: Warren RB, Blauvelt A, Poulin Y, Efficacy and safety of risankizumab vs.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.